News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Ventracor Limited Announce 250th Implant of VentrAssist Left Ventricular Assist Device (LVAD)
May 6, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Sydney, May 6, 2008 (ABN Newswire) - Ventracor Limited (ASX:VCR)(US:VTCRY) today announced that there have now been more than 250 patient implants of the VentrAssist(R) Left Ventricular Assist Device (LVAD).
Twitter
LinkedIn
Facebook
Email
Print
Australia
MORE ON THIS TOPIC
Regulatory
Biogen, Eisai’s Leqembi Suffers Overseas Setbacks as UK Denies Coverage, Australia Denies Approval
March 7, 2025
·
2 min read
·
Tristan Manalac
Genetown
The Best Way to Answer Salary Interview Questions
June 11, 2024
·
4 min read
·
Lorenzo Soliman
Drug Development
Kazia’s Star Asset Suffers Surprise Letdown in Global Glioblastoma Study
August 2, 2022
·
3 min read
·
Tristan Manalac
Drug Development
Sapience, Intensity, Kazia and Transcenta Tout Early Success at ASCO
June 3, 2022
·
3 min read
·
Vanessa Doctor, RN
